In January 2020, the FDA approved avapritinib for the treatment of adult patients with inoperable or metastatic PDGFRA exon 18‐mutant GIST, including those with the PDGFRA D842V mutation [51, 52]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.